Evaluation of Efficacy of Two Different Doses of Intravenous Lidocaine in Patients with Chronic Pain

A. Ghai, Bharti Verma, Kanika Rohilla
{"title":"Evaluation of Efficacy of Two Different Doses of Intravenous Lidocaine in Patients with Chronic Pain","authors":"A. Ghai, Bharti Verma, Kanika Rohilla","doi":"10.4103/mamcjms.mamcjms_7_23","DOIUrl":null,"url":null,"abstract":"Background: An intravenous infusion of lidocaine has been used on numerous occasions to produce analgesia in neuropathic pain. It has been shown to be beneficial for the treatment of variety of neuropathic pain states in a wide range of dosage, from 2 to 7.5 mg/kg. The aim of our study was to evaluate the efficacy of two different doses of intravenous lidocaine (3 and 4 mg/kg) in patients with chronic pain. Methods: Patients above the age of 18 years suffering from chronic pain due to postherpetic neuralgia, post-surgical scar pain, chronic low back pain having numeric analogue scale (NAS) pain score of ≥3 without satisfactory pain relief from conservative treatment were randomised to receive either 3 mg/kg or 4 mg/kg intravenous lidocaine in 250 mL normal saline infusions weekly over a period of 1 hour for 3 weeks. NAS was measured before starting each infusion, immediately after completion of infusion, 2 and 24 hours, 7th day, 14th day, 21st day, and 28th day. Results: NAS score at first hour and 24th hour was significantly reduced (P = 0.001), after each infusion [7th, 14th day] in both the groups. There was no statistical difference in pain score among both groups except for day 7 (P value 0.04). Reduction in NAS score was also present on 21st and 28th day in both groups, but it did not reach a significant value. On 28th day, NAS score values showed increasing trend. Duration of pain relief was around 1 week after each infusion in both groups. Conclusion: Intravenous lidocaine at a dose of 3 mg/kg or 4 mg/kg was effective in reducing pain in patients with chronic pain. The analgesic effect was not different among both groups. Trend of greater response was observed with 4 mg/kg dose.","PeriodicalId":32900,"journal":{"name":"MAMC Journal of Medical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MAMC Journal of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/mamcjms.mamcjms_7_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: An intravenous infusion of lidocaine has been used on numerous occasions to produce analgesia in neuropathic pain. It has been shown to be beneficial for the treatment of variety of neuropathic pain states in a wide range of dosage, from 2 to 7.5 mg/kg. The aim of our study was to evaluate the efficacy of two different doses of intravenous lidocaine (3 and 4 mg/kg) in patients with chronic pain. Methods: Patients above the age of 18 years suffering from chronic pain due to postherpetic neuralgia, post-surgical scar pain, chronic low back pain having numeric analogue scale (NAS) pain score of ≥3 without satisfactory pain relief from conservative treatment were randomised to receive either 3 mg/kg or 4 mg/kg intravenous lidocaine in 250 mL normal saline infusions weekly over a period of 1 hour for 3 weeks. NAS was measured before starting each infusion, immediately after completion of infusion, 2 and 24 hours, 7th day, 14th day, 21st day, and 28th day. Results: NAS score at first hour and 24th hour was significantly reduced (P = 0.001), after each infusion [7th, 14th day] in both the groups. There was no statistical difference in pain score among both groups except for day 7 (P value 0.04). Reduction in NAS score was also present on 21st and 28th day in both groups, but it did not reach a significant value. On 28th day, NAS score values showed increasing trend. Duration of pain relief was around 1 week after each infusion in both groups. Conclusion: Intravenous lidocaine at a dose of 3 mg/kg or 4 mg/kg was effective in reducing pain in patients with chronic pain. The analgesic effect was not different among both groups. Trend of greater response was observed with 4 mg/kg dose.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
两种不同剂量利多卡因静脉注射治疗慢性疼痛的疗效评价
背景:静脉输注利多卡因已多次用于神经性疼痛的镇痛。已经证明,在2至7.5的宽剂量范围内,它对治疗各种神经性疼痛状态是有益的 mg/kg。我们研究的目的是评估两种不同剂量静脉注射利多卡因(3和4 mg/kg)治疗慢性疼痛患者。方法:将18岁以上因带状疱疹后神经痛引起的慢性疼痛、术后瘢痕疼痛、数值模拟量表(NAS)疼痛评分≥3且保守治疗后疼痛缓解不满意的慢性腰痛患者随机分为3组 mg/kg或4 mg/kg利多卡因静脉滴注250 每周输注mL生理盐水,时间为1小时,持续3周。在每次输注开始前、输注完成后立即、2小时和24小时、第7天、第14天、第21天和第28天测量NAS。结果:NAS评分在第1小时和第24小时明显下降(P = 0.001),在两组每次输注后[7,14d]。除第7天外,两组的疼痛评分均无统计学差异(P值0.04)。NAS评分在第21天和第28天也有所下降,但没有达到显著值。第28天,NAS评分呈上升趋势。两组患者每次输注后疼痛缓解的持续时间均为1周左右。结论:静脉注射利多卡因,剂量为3 mg/kg或4 mg/kg对减轻慢性疼痛患者的疼痛是有效的。两组患者的镇痛效果无差异。4 mg/kg剂量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
20 weeks
期刊最新文献
The clinical, sociodemographic, and pharmacotherapeutic characteristics influencing quality of life in patients with epilepsy Should planning of cervical pedicle screws be race specific? Computed tomography–based morphometric analysis A Prospective Clinical Evaluation of Adhesive Small Bowel Obstruction in Infants and Children A randomized controlled study to compare the dose requirement of oxytocin for management of uterine atony in patients receiving prophylactic phenylephrine during caesarean delivery Artificial intelligence and healthcare
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1